Structural insights into probe-dependent positive allosterism of the GLP-1 receptor
- PMID: 32690941
- DOI: 10.1038/s41589-020-0589-7
Structural insights into probe-dependent positive allosterism of the GLP-1 receptor
Abstract
Drugs that promote the association of protein complexes are an emerging therapeutic strategy. We report discovery of a G protein-coupled receptor (GPCR) ligand that stabilizes an active state conformation by cooperatively binding both the receptor and orthosteric ligand, thereby acting as a 'molecular glue'. LSN3160440 is a positive allosteric modulator of the GLP-1R optimized to increase the affinity and efficacy of GLP-1(9-36), a proteolytic product of GLP-1(7-36). The compound enhances insulin secretion in a glucose-, ligand- and GLP-1R-dependent manner. Cryo-electron microscopy determined the structure of the GLP-1R bound to LSN3160440 in complex with GLP-1 and heterotrimeric Gs. The modulator binds high in the helical bundle at an interface between TM1 and TM2, allowing access to the peptide ligand. Pharmacological characterization showed strong probe dependence of LSN3160440 for GLP-1(9-36) versus oxyntomodulin that is driven by a single residue. Our findings expand protein-protein modulation drug discovery to uncompetitive, active state stabilizers for peptide hormone receptors.
Similar articles
-
Discovery of a potential positive allosteric modulator of glucagon-like peptide 1 receptor through virtual screening and experimental study.J Comput Aided Mol Des. 2019 Nov;33(11):973-981. doi: 10.1007/s10822-019-00254-4. Epub 2019 Nov 22. J Comput Aided Mol Des. 2019. PMID: 31758355
-
Positive Allosteric Modulation of the Glucagon-like Peptide-1 Receptor by Diverse Electrophiles.J Biol Chem. 2016 May 13;291(20):10700-15. doi: 10.1074/jbc.M115.696039. Epub 2016 Mar 14. J Biol Chem. 2016. PMID: 26975372 Free PMC article.
-
Molecular insights into ago-allosteric modulation of the human glucagon-like peptide-1 receptor.Nat Commun. 2021 Jun 18;12(1):3763. doi: 10.1038/s41467-021-24058-z. Nat Commun. 2021. PMID: 34145245 Free PMC article.
-
Discovery and pharmacology of the covalent GLP-1 receptor (GLP-1R) allosteric modulator BETP: A novel tool to probe GLP-1R pharmacology.Adv Pharmacol. 2020;88:173-191. doi: 10.1016/bs.apha.2020.02.001. Epub 2020 Mar 2. Adv Pharmacol. 2020. PMID: 32416867 Review.
-
An Overview, Advantages and Therapeutic Potential of Nonpeptide Positive Allosteric Modulators of Glucagon-Like Peptide-1 Receptor.ChemMedChem. 2019 Mar 5;14(5):514-521. doi: 10.1002/cmdc.201800699. Epub 2019 Jan 31. ChemMedChem. 2019. PMID: 30609277 Review.
Cited by
-
Deep Learning Dynamic Allostery of G-Protein-Coupled Receptors.JACS Au. 2023 Nov 2;3(11):3165-3180. doi: 10.1021/jacsau.3c00503. eCollection 2023 Nov 27. JACS Au. 2023. PMID: 38034960 Free PMC article.
-
Human GLP1R variants affecting GLP1R cell surface expression are associated with impaired glucose control and increased adiposity.Nat Metab. 2023 Oct;5(10):1673-1684. doi: 10.1038/s42255-023-00889-6. Epub 2023 Sep 14. Nat Metab. 2023. PMID: 37709961
-
Structural insights into ligand recognition and subtype selectivity of the human melanocortin-3 and melanocortin-5 receptors.Cell Discov. 2023 Jul 31;9(1):81. doi: 10.1038/s41421-023-00586-4. Cell Discov. 2023. PMID: 37524700 Free PMC article.
-
Selective polypeptide ligand binding to the extracellular surface of the transmembrane domains of the class B GPCRs GLP-1R and GCGR.iScience. 2023 May 19;26(6):106918. doi: 10.1016/j.isci.2023.106918. eCollection 2023 Jun 16. iScience. 2023. PMID: 37332600 Free PMC article.
-
Affinity selection of double-click triazole libraries for rapid discovery of allosteric modulators for GLP-1 receptor.Proc Natl Acad Sci U S A. 2023 Mar 14;120(11):e2220767120. doi: 10.1073/pnas.2220767120. Epub 2023 Mar 9. Proc Natl Acad Sci U S A. 2023. PMID: 36893261 Free PMC article.
References
-
- Marso, S. P. et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 375, 311–322 (2016). - DOI
-
- Marso, S. P. et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 375, 1834–1844 (2016). - DOI
-
- Hernandez, A. F. et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 392, 1519–1529 (2018). - DOI
-
- Gerstein, H. C. et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394, 121–130 (2019). - DOI
-
- Wootten, D. et al. Allosteric modulation of endogenous metabolites as an avenue for drug discovery. Mol. Pharmacol. 82, 281–290 (2012). - DOI
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
